Share on StockTwits

Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “neutral” rating reaffirmed by Goldman Sachs in a research note issued on Friday.

Shares of Amarin Co. plc (NASDAQ:AMRN) remained flat at $1.66 during during mid-day trading trading on Friday. 2,575,136 shares of the company’s stock traded hands. Amarin Co. plc has a one year low of $1.28 and a one year high of $7.40. The stock has a 50-day moving average of $1.62 and a 200-day moving average of $1.65. The company’s market cap is $287.0 million. Amarin Co. plc also was the target of some unusual options trading on Thursday. Stock investors bought 216 put options on the company. This is an increase of 332% compared to the typical volume of 50 put options.

Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.01. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate of $12.86 million. The company’s revenue for the quarter was up 129.1% on a year-over-year basis. On average, analysts predict that Amarin Co. plc will post $-0.55 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on AMRN. Analysts at MKM Partners reiterated a “fair value” rating on shares of Amarin Co. plc in a research note on Monday, May 12th. They now have a $1.50 price target on the stock, down previously from $2.00. Analysts at Aegis reiterated a “hold” rating on shares of Amarin Co. plc in a research note on Monday, May 12th. Eleven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $3.58.

Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.